NYSE$AVTR
Avantor Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Reported financial results for the quarter and year ended December 31, 2019.
Avantor's Q4 2019 results showed strong sales, particularly in the biopharma business, margin expansion, and robust cash flow generation. Net sales increased by 3.4% to $1.52 billion, net income increased to $70.6 million, and adjusted EPS increased 89.9% to $0.19.
- Net sales reached $1.52 billion with 3.4% increase.
- Net income increased to $70.6 million.
- Adjusted EBITDA increased 11.8% to $263.6 million.
- Adjusted EPS increased 89.9% to $0.19.
Headline financials
Revenue & EPS history
Avantor · Revenue · Quarterly
$1.52B
Forward guidance
The Company projects organic sales to be up 4% to 6% for 2020. Adjusted EBITDA is projected to be in the range of $1.090-1.135 billion, or an increase of 6% to 10%. Guidance for full-year adjusted EPS is $0.74-0.79, up 27-36%. Free cash flow is expected to be in the range of $450-500 million, up 50-65% from 2019.
Tailwinds
- Organic sales to be up 4% to 6% for 2020
- Adjusted EBITDA is projected to be in the range of $1.090-1.135 billion, or an increase of 6% to 10%
- Full-year adjusted EPS is $0.74-0.79, up 27-36%
- Free cash flow is expected to be in the range of $450-500 million, up 50-65% from 2019.
- Current foreign exchange rates (e.g., Euro 1.11)
Headwinds
- The timing and cost of future restructuring activities
- Charges related to the early retirement of debt
- Changes in tax rates
- Other non-recurring items.
- Factors described in “Risk Factors” in our Registration Statement on Form S-1 (File No. 333-229578) and our Form 10-K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.6%
Avg return
Earnings day
-0.9%
Avg return
5 days after
+1.3%
Avg return
30 days after
47%
15 / 32 earnings
Positive
+21.7%
Q1 2020
Best reaction
-23.2%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | +1.5% | +16.0% | |
| Q4 2025 | -13.6% | -17.6% | -28.9% | |
| Q3 2025 | -23.2% | -22.5% | -22.2% | |
| Q1 2025 | -16.6% | -16.2% | -18.1% | |
| Q4 2024 | -11.7% | -16.8% | -19.4% | |
| Q3 2024 | -2.7% | -3.5% | -10.7% | |
| Q2 2024 | +15.0% | +17.2% | +12.4% | |
| Q1 2024 | -4.3% | -2.9% | -4.0% | |
| Q4 2023 | +8.6% | +7.3% | +13.3% | |
| Q3 2023 | -12.1% | -10.8% | +4.1% | |
| Q2 2023 | -9.9% | -7.9% | -4.6% | |
| Q1 2023 | +8.0% | +7.8% | +10.2% | |
| Q4 2022 | -5.9% | -1.9% | +0.9% | |
| Q3 2022 | -1.8% | -6.1% | +4.4% | |
| Q2 2022 | -8.6% | -7.9% | -19.6% | |
| Q1 2022 | +8.4% | +7.4% | +12.1% | |
| Q4 2021 | -2.9% | -3.6% | -13.5% | |
| Q3 2021 | +9.3% | +7.9% | +7.3% | |
| Q2 2021 | +0.3% | +0.9% | +4.8% | |
| Q1 2021 | -1.4% | -5.7% | -3.0% | |
| Q4 2020 | -2.2% | -1.9% | -9.9% | |
| Q3 2020 | -5.5% | -5.9% | +5.3% | |
| Q2 2020 | +16.6% | +18.3% | +16.0% | |
| Q1 2020 | +21.7% | +22.8% | +37.4% | |
| Q4 2019 | -11.4% | -7.5% | -21.5% | |
| Q3 2018 | +2.7% | -4.2% | +17.4% | |
| Q3 2019 | +2.7% | -4.2% | +17.4% | |
| Q2 2019 | +4.2% | +5.2% | +7.3% | |
| Q1 2018 | +4.2% | +5.2% | +7.3% | |
| Q2 2018 | +4.2% | +5.2% | +7.3% | |
| Q1 2019 | +4.2% | +5.2% | +7.3% | |
| Q4 2018 | +4.2% | +5.2% | +7.3% | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro